^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABBV-453
i
Other names: ABBV-453
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
Bcl2 inhibitor
Related drugs:
23d
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=34, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=360 --> 34 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Feb 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453
5ms
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
P1, N=80, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events
|
Gazyva (obinutuzumab) • ABBV-453
9ms
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
P1, N=80, Not yet recruiting, AbbVie
New P1 trial • Adverse events
|
Gazyva (obinutuzumab) • ABBV-453
10ms
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=360, Recruiting, AbbVie | Trial completion date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026
Trial completion date • Trial primary completion date • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453
1year
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=360, Recruiting, AbbVie | N=48 --> 360
Enrollment change • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453
over1year
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=48, Recruiting, AbbVie | N=21 --> 48
Enrollment change • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
lenalidomide • Darzalex (daratumumab) • ABBV-453
over1year
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=21, Recruiting, AbbVie | Trial primary completion date: Aug 2025 --> Apr 2026
Trial primary completion date • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Chr t(11;14)
|
ABBV-453
over2years
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=21, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
ABBV-453
over2years
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
P1, N=21, Not yet recruiting, AbbVie
New P1 trial • Adverse events • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
ABBV-453
Share via
